Sparian Biosciences
Vilomi Tringuk (Patel) currently serves as VP of Corporate and Program Strategy at Sparian Biosciences, focusing on managing a portfolio of programs and strategic initiatives. Previously, Tringuk held the position of Sr. Director of Portfolio Management at Shattuck Labs, where responsibilities included leading strategic program and alliance management for various projects from preclinical to clinical stages. Earlier experience includes roles at Seqirus and Shire, focusing on program management and technology transfer for new product introductions, as well as significant project management and engineering roles at Genzyme and Integra LifeSciences. Tringuk holds an MBA from Babson F.W. Olin Graduate School of Business and a B.S. in Biomedical Engineering from The Johns Hopkins University.
This person is not in any teams
This person is not in any offices
Sparian Biosciences
Sparian Biosciences is an early-stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. Diseases of the central nervous system represent a major unmet need but recently there has been little innovation and development. Sparian was co-founded by Gavril Pasternak, MD PhD and Jeff Reich, MD to develop therapeutics targeting the brain through innovative science and novel drug discovery. Currently, we have 4 programs addressing various aspects of the opioid crisis - a crisis in urgent need of innovation. Two of our compounds come from the Pasternak Lab at Memorial Sloan Kettering Cancer Center, one comes from the USC Michelson Center for Convergent Bioscience and one comes from a collaboration with Washington University. Core to our strategy, we have ongoing scientific and clinical collaborations with MSKCC, Washington University, St. Louis College of Pharmacy, Rutgers University Medical School, University of Florida, and the U.S. Department of Defense. Sparian is based out of BioLabs@NYULangone in NYC, a national biotech incubator, and is a member of the StartupNY program.